135 related articles for article (PubMed ID: 16932252)
1. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
Santoro M; Carlomagno F
Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):42-52. PubMed ID: 16932252
[TBL] [Abstract][Full Text] [Related]
2. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
4. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
5. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
6. New approaches to thyroid cancer.
Cohen EE
Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
[No Abstract] [Full Text] [Related]
7. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
9. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
10. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
11. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.
De Falco V; Castellone MD; De Vita G; Cirafici AM; Hershman JM; Guerrero C; Fusco A; Melillo RM; Santoro M
Cancer Res; 2007 Jan; 67(1):381-90. PubMed ID: 17210721
[TBL] [Abstract][Full Text] [Related]
12. [BRAF gene mutation in thyroid cancer].
Kopczyńska E; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
Ezzat S; Huang P; Dackiw A; Asa SL
Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
[TBL] [Abstract][Full Text] [Related]
14. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
[TBL] [Abstract][Full Text] [Related]
15. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.
Kodama Y; Asai N; Kawai K; Jijiwa M; Murakumo Y; Ichihara M; Takahashi M
Cancer Sci; 2005 Mar; 96(3):143-8. PubMed ID: 15771616
[TBL] [Abstract][Full Text] [Related]
16. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.
Couto JP; Prazeres H; Castro P; Lima J; Máximo V; Soares P; Sobrinho-Simões M
J Clin Pathol; 2009 May; 62(5):414-21. PubMed ID: 19147628
[TBL] [Abstract][Full Text] [Related]
17. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
18. Role of BRAF in thyroid oncogenesis.
Caronia LM; Phay JE; Shah MH
Clin Cancer Res; 2011 Dec; 17(24):7511-7. PubMed ID: 21900390
[TBL] [Abstract][Full Text] [Related]
19. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
Kojic KL; Kojic SL; Wiseman SM
Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of BRAF mutation in thyroid carcinoma.
Puxeddu E; Durante C; Avenia N; Filetti S; Russo D
Trends Endocrinol Metab; 2008; 19(4):138-45. PubMed ID: 18337114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]